NCT04401579 · BASELINE

Baseline characteristics

Adaptive COVID-19 Treatment Trial 2 (ACTT-2) · Source last updated 2022-03-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
515
group Id
BG001
value
518
group Id
BG002
value
1033
units
Participants

groups

description
200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
id
BG000
title
Remdesivir Plus Baricitinib
description
200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
id
BG001
title
Remdesivir Plus Placebo
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
<=18 years
measurements
group Id
BG000
value
368
group Id
BG001
value
360
group Id
BG002
value
728
title
Between 18 and 65 years
measurements
group Id
BG000
value
147
group Id
BG001
value
158
group Id
BG002
value
305
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
15.4
value
55.0
group Id
BG001
spread
16.0
value
55.8
group Id
BG002
spread
15.7
value
55.4
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
196
group Id
BG001
value
185
group Id
BG002
value
381
title
Female
measurements
group Id
BG000
value
319
group Id
BG001
value
333
group Id
BG002
value
652
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
263
group Id
BG001
value
268
group Id
BG002
value
531
title
Hispanic or Latino
measurements
group Id
BG000
value
246
group Id
BG001
value
240
group Id
BG002
value
486
title
Not Hispanic or Latino
measurements
group Id
BG000
value
6
group Id
BG001
value
10
group Id
BG002
value
16
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Ethnicity (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
2
group Id
BG001
value
8
group Id
BG002
value
10
title
American Indian or Alaska Native
measurements
group Id
BG000
value
49
group Id
BG001
value
52
group Id
BG002
value
101
title
Asian
measurements
group Id
BG000
value
4
group Id
BG001
value
7
group Id
BG002
value
11
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
77
group Id
BG001
value
79
group Id
BG002
value
156
title
Black or African American
measurements
group Id
BG000
value
251
group Id
BG001
value
245
group Id
BG002
value
496
title
White
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
More than one race
measurements
group Id
BG000
value
132
group Id
BG001
value
127
group Id
BG002
value
259
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
11
group Id
BG001
value
11
group Id
BG002
value
22
title
South Korea
categories
measurements
group Id
BG000
value
22
group Id
BG001
value
22
group Id
BG002
value
44
title
Singapore
categories
measurements
group Id
BG000
value
441
group Id
BG001
value
444
group Id
BG002
value
885
title
United States
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
Japan
categories
measurements
group Id
BG000
value
4
group Id
BG001
value
5
group Id
BG002
value
9
title
Denmark
categories
measurements
group Id
BG000
value
35
group Id
BG001
value
33
group Id
BG002
value
68
title
Mexico
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
United Kingdom
categories
measurements
group Id
BG000
value
2
group Id
BG001
value
1
group Id
BG002
value
3
title
Spain
param Type
COUNT_OF_PARTICIPANTS
title
Region of Enrollment
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
176
group Id
BG001
value
191
group Id
BG002
value
367
title
Severe Disease Severity
measurements
group Id
BG000
value
339
group Id
BG001
value
327
group Id
BG002
value
666
title
Moderate Disease Severity
description
Severe disease was defined as hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive or non-invasive ventilation, or high flow oxygen Moderate disease was defined as hospitalized, requiring supplemental oxygen or not requiring supplemental oxygen. Disease severity was as defined at the time or randomization.
param Type
COUNT_OF_PARTICIPANTS
title
Disease severity
unit Of Measure
Participants

Complete source fields

denoms

counts
group Id
BG000
value
515
group Id
BG001
value
518
group Id
BG002
value
1033
units
Participants

groups

description
200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
id
BG000
title
Remdesivir Plus Baricitinib
description
200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
id
BG001
title
Remdesivir Plus Placebo
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
<=18 years
measurements
group Id
BG000
value
368
group Id
BG001
value
360
group Id
BG002
value
728
title
Between 18 and 65 years
measurements
group Id
BG000
value
147
group Id
BG001
value
158
group Id
BG002
value
305
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
15.4
value
55.0
group Id
BG001
spread
16.0
value
55.8
group Id
BG002
spread
15.7
value
55.4
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
196
group Id
BG001
value
185
group Id
BG002
value
381
title
Female
measurements
group Id
BG000
value
319
group Id
BG001
value
333
group Id
BG002
value
652
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
263
group Id
BG001
value
268
group Id
BG002
value
531
title
Hispanic or Latino
measurements
group Id
BG000
value
246
group Id
BG001
value
240
group Id
BG002
value
486
title
Not Hispanic or Latino
measurements
group Id
BG000
value
6
group Id
BG001
value
10
group Id
BG002
value
16
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Ethnicity (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
2
group Id
BG001
value
8
group Id
BG002
value
10
title
American Indian or Alaska Native
measurements
group Id
BG000
value
49
group Id
BG001
value
52
group Id
BG002
value
101
title
Asian
measurements
group Id
BG000
value
4
group Id
BG001
value
7
group Id
BG002
value
11
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
77
group Id
BG001
value
79
group Id
BG002
value
156
title
Black or African American
measurements
group Id
BG000
value
251
group Id
BG001
value
245
group Id
BG002
value
496
title
White
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
More than one race
measurements
group Id
BG000
value
132
group Id
BG001
value
127
group Id
BG002
value
259
title
Unknown or Not Reported
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
11
group Id
BG001
value
11
group Id
BG002
value
22
title
South Korea
categories
measurements
group Id
BG000
value
22
group Id
BG001
value
22
group Id
BG002
value
44
title
Singapore
categories
measurements
group Id
BG000
value
441
group Id
BG001
value
444
group Id
BG002
value
885
title
United States
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
Japan
categories
measurements
group Id
BG000
value
4
group Id
BG001
value
5
group Id
BG002
value
9
title
Denmark
categories
measurements
group Id
BG000
value
35
group Id
BG001
value
33
group Id
BG002
value
68
title
Mexico
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
United Kingdom
categories
measurements
group Id
BG000
value
2
group Id
BG001
value
1
group Id
BG002
value
3
title
Spain
param Type
COUNT_OF_PARTICIPANTS
title
Region of Enrollment
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
176
group Id
BG001
value
191
group Id
BG002
value
367
title
Severe Disease Severity
measurements
group Id
BG000
value
339
group Id
BG001
value
327
group Id
BG002
value
666
title
Moderate Disease Severity
description
Severe disease was defined as hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive or non-invasive ventilation, or high flow oxygen Moderate disease was defined as hospitalized, requiring supplemental oxygen or not requiring supplemental oxygen. Disease severity was as defined at the time or randomization.
param Type
COUNT_OF_PARTICIPANTS
title
Disease severity
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice